<DOC>
	<DOCNO>NCT01352845</DOCNO>
	<brief_summary>This study look new vaccine might prevent meningococcal disease , study immune response elicit vaccine give healthy young adult . The study also look safety new vaccine well tolerate .</brief_summary>
	<brief_title>A Trial Assess Safety , Tolerability , Immunogenicity Bivalent rLP2086 Vaccine When Given Healthy Young Adults Aged &gt; =18 &lt; 26 Years .</brief_title>
	<detailed_description />
	<criteria>1 . Male female subject age &gt; =18 &lt; 26 year time enrollment . 2 . Healthy subject determine medical history , physical examination , judgment investigator . 3 . Negative urine pregnancy test female subject . 1 . Previous vaccination meningococcal serogroup B vaccine . 2 . Subjects schedule receive 1 dos HPV vaccine part 3dose series period Visit 1 28 day second vaccination . 3 . Subjects receive allergen immunotherapy nonlicensed product receive allergen immunotherapy license product stable maintenance dos . 4 . A know suspected defect immune system would prevent immune response vaccine , subject congenital acquire defect B cell function , receive chronic systemic ( oral , intravenous , intramuscular ) corticosteroid therapy , receive immunosuppressive therapy . Subjects United States terminal complement deficiency exclude participation study . 5 . Significant neurological disorder history seizure ( exclude simple febrile seizure ) . 6 . Current chronic use systemic antibiotic . 7 . Received investigational vaccine , drug , device within 28 day administration first study vaccination . 8 . Any neuroinflammatory autoimmune condition , include , limited , transverse myelitis , uveitis , optic neuritis , multiple sclerosis .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>25 Years</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>